Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation

Sponsor
Zhanghao (Other)
Overall Status
Recruiting
CT.gov ID
NCT03002207
Collaborator
(none)
100
1
4
74
1.4

Study Details

Study Description

Brief Summary

In this prospective study the investigators seek to evaluate clinical outcomes after repairing the defect of intervertebral disc with autologous BMSC/gelatin sponge during microendoscopic discectomy for participants of lumbar disc herniation.

Condition or Disease Intervention/Treatment Phase
  • Device: Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge
  • Procedure: The defect is sutured
N/A

Detailed Description

The participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Prospective, Comparative Study to Evaluate Effectiveness of Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation
Actual Study Start Date :
Oct 1, 2016
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: The defect is repaired and sutured

Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured.

Device: Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge
Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Procedure: The defect is sutured
Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.

Experimental: The defect is repaired but not sutured

Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy.

Device: Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge
Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Experimental: The defect is sutured but not repaired

Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Procedure: The defect is sutured
Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.

No Intervention: The defect is neither sutured nor repaired

Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Outcome Measures

Primary Outcome Measures

  1. Changes from baseline in Oswestry Disability Index(ODI) [Baseline, post-op 3 months, 6 months,12 months]

    The self-completed questionnaire contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel.Each topic category is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. The patient then checks the statement which most closely resembles their situation. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.

Secondary Outcome Measures

  1. Changes from baseline in Visual Analogue Scale(VAS) [Baseline, post-op 3 months, 6 months,12 months]

    Self reported pain using a 10-point visual analogue scale (0=no pain;10=pain as bad as can be)

  2. Changes from baseline in The Short Form (36) Health Survey(SF-36) [Baseline, post-op 3 months, 6 months,12 months]

    The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

  3. Change from Baseline in Magnetic Resonance Classification of Lumbar Intervertebral Disc Degeneration(Pfirrmann classification) [Baseline, post-op 12 months]

    The Pfirrmann grading system assesses degenerated intervertebral discs by MRI for the asymmetry in disc structure, distinction of the nucleus and the annulus, signal intensity of intervertebral discs and height of intervertebral discs and assigns grade I to V for disc degeneration。

  4. Change from Baseline in The Height of Disc on MRI Scans [Baseline, post-op 12 months]

    Using imaging software, physicians will measure disc height at the treatment discs on the midline T1 sagittal view

  5. Change from Baseline in The Size of Disc Protrusion [Baseline, post-op 12 months]

    We will measure the anteroposterior (AP) size of the disc protrusions that required treatment

Other Outcome Measures

  1. The Medical Records [1 months after hospital discharge]

    The Medical Records including operative time、blood loss and hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Participants with signs and symptoms of lumbar disc herniation requiring surgical treatment after conservative management;

  2. Radiological data on CT/MRI obtained within a period prior to enrollment;

  3. Participants give written informed consent before enrollment.

Exclusion Criteria:
  1. If participants had an incomplete medical record;

  2. Participants had spine tumor, spine infection, previous underwent lumbar surgery, or revision surgery.

  3. Participants are taking uninterruptible anticoagulation therapy.

  4. Dementia and/or inability to give informed consent.

  5. MRI contraindication (e.g. cerebral aneurysm clips, cochlear implants, pacemaker, implanted biostimulators);

  6. Pregnancy;

  7. Participation in other clinical trial within the last 30 days.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tianjin Hospital Tianjin China 300211

Sponsors and Collaborators

  • Zhanghao

Investigators

  • Study Chair: Xinlong Ma, Tianjin Hospital Of Tianjin

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zhanghao, Tianjin Hospital, Tianjin Hospital
ClinicalTrials.gov Identifier:
NCT03002207
Other Study ID Numbers:
  • 2016(001)
First Posted:
Dec 23, 2016
Last Update Posted:
Oct 21, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 21, 2021